The firm upped its price target for the Israeli pharmaceutical company to $65 from $61, based on the Allergan (AGN) Generics deal that's expected to close any day now, TheFly reports.
Teva's deal with Allergen would also lift some of the burden on the stock generated by Copaxone, the firm noted.
Shares of Teva are down 0.29% to $54.06 in afternoon trading on Monday.
Separately, TheStreet Ratings objectively rated this stock according to its "risk-adjusted" total return prospect over a 12-month investment horizon. Not based on the news in any given day, the rating may differ from Jim Cramer's view or that of this articles's author. TheStreet Ratings has this to say about the recommendation:
We rate TEVA PHARMACEUTICALS as a Buy with a ratings score of B. This is driven by several positive factors, which we believe should have a greater impact than any weaknesses, and should give investors a better performance opportunity than most stocks we cover. The company's strengths can be seen in multiple areas, such as its increase in net income, attractive valuation levels, expanding profit margins, growth in earnings per share and largely solid financial position with reasonable debt levels by most measures. We feel its strengths outweigh the fact that the company has had somewhat disappointing return on equity.
You can view the full analysis from the report here: TEVATEVA data by YCharts